<i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i>
An emerging need for new classes of antibiotics is, on the one hand, evident as antimicrobial resistance continues to rise. On the other hand, the awareness of the pros and cons of chemically synthesized compounds’ extensive use leads to a search for new metabolites in already known reservoirs. Prev...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-04-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/9/5/319 |
| _version_ | 1797569615959687168 |
|---|---|
| author | Magdalena Pajor Zirui Ray Xiong Randy W. Worobo Piotr Szweda |
| author_facet | Magdalena Pajor Zirui Ray Xiong Randy W. Worobo Piotr Szweda |
| author_sort | Magdalena Pajor |
| collection | DOAJ |
| description | An emerging need for new classes of antibiotics is, on the one hand, evident as antimicrobial resistance continues to rise. On the other hand, the awareness of the pros and cons of chemically synthesized compounds’ extensive use leads to a search for new metabolites in already known reservoirs. Previous research showed that <i>Paenibacillus</i> strain (<i>P. alvei</i> MP1) recovered from a buckwheat honey sample presented a wide spectrum of antimicrobial activity against both Gram-positive and Gram-negative pathogens. Recent investigation has confirmed that <i>P. alvei</i> MP1 (deposited at DDBJ/ENA/GenBank under the accession WSQB00000000) produces a proteinaceous, heat-stable compound(s) with the maximum antimicrobial production obtained after 18 h of <i>P. alvei</i> MP1 growth in LB medium at 37 °C with continuous shaking at 200 RPM. The highest activity was found in the 40% ammonium sulfate precipitate, with high activity also remaining in the 50% and 60% ammonium sulfate precipitates. Moderate to high antimicrobial activity that is insensitive to proteases or heat treatment, was confirmed against pathogenic bacteria that included <i>L. monocytogenes</i> FSL – X1-0001 (strain 10403S), <i>S. aureus</i> L1 – 0030 and <i>E. coli</i> O157: H7. Further studies, including de novo sequencing of peptides by mass spectrometry, are in progress. |
| first_indexed | 2024-03-10T20:14:08Z |
| format | Article |
| id | doaj.art-122b15d2bcb34f13bf4e81e27bb14165 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T20:14:08Z |
| publishDate | 2020-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-122b15d2bcb34f13bf4e81e27bb141652023-11-19T22:41:30ZengMDPI AGPathogens2076-08172020-04-019531910.3390/pathogens9050319<i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i>Magdalena Pajor0Zirui Ray Xiong1Randy W. Worobo2Piotr Szweda3Department of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, G. Narutowicza Street 11/12, 80-233 Gdansk, PolandDepartment of Food Science, Cornell University, Stocking Hall, Ithaca, New York, NY 14853-7201, USADepartment of Food Science, Cornell University, Stocking Hall, Ithaca, New York, NY 14853-7201, USADepartment of Pharmaceutical Technology and Biochemistry, Faculty of Chemistry, Gdansk University of Technology, G. Narutowicza Street 11/12, 80-233 Gdansk, PolandAn emerging need for new classes of antibiotics is, on the one hand, evident as antimicrobial resistance continues to rise. On the other hand, the awareness of the pros and cons of chemically synthesized compounds’ extensive use leads to a search for new metabolites in already known reservoirs. Previous research showed that <i>Paenibacillus</i> strain (<i>P. alvei</i> MP1) recovered from a buckwheat honey sample presented a wide spectrum of antimicrobial activity against both Gram-positive and Gram-negative pathogens. Recent investigation has confirmed that <i>P. alvei</i> MP1 (deposited at DDBJ/ENA/GenBank under the accession WSQB00000000) produces a proteinaceous, heat-stable compound(s) with the maximum antimicrobial production obtained after 18 h of <i>P. alvei</i> MP1 growth in LB medium at 37 °C with continuous shaking at 200 RPM. The highest activity was found in the 40% ammonium sulfate precipitate, with high activity also remaining in the 50% and 60% ammonium sulfate precipitates. Moderate to high antimicrobial activity that is insensitive to proteases or heat treatment, was confirmed against pathogenic bacteria that included <i>L. monocytogenes</i> FSL – X1-0001 (strain 10403S), <i>S. aureus</i> L1 – 0030 and <i>E. coli</i> O157: H7. Further studies, including de novo sequencing of peptides by mass spectrometry, are in progress.https://www.mdpi.com/2076-0817/9/5/319<i>Paenibacillus alvei</i>antimicrobial activity<i>Staphylococcus aureus</i><i>Listeria monocytogenes</i><i>Escherichia coli</i>antimicrobial compounds |
| spellingShingle | Magdalena Pajor Zirui Ray Xiong Randy W. Worobo Piotr Szweda <i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> Pathogens <i>Paenibacillus alvei</i> antimicrobial activity <i>Staphylococcus aureus</i> <i>Listeria monocytogenes</i> <i>Escherichia coli</i> antimicrobial compounds |
| title | <i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> |
| title_full | <i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> |
| title_fullStr | <i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> |
| title_full_unstemmed | <i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> |
| title_short | <i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i> |
| title_sort | i paenibacillus alvei mp1 i as a producer of the proteinaceous compound with activity against important human pathogens including i staphylococcus aureus i and i listeria monocytogenes i |
| topic | <i>Paenibacillus alvei</i> antimicrobial activity <i>Staphylococcus aureus</i> <i>Listeria monocytogenes</i> <i>Escherichia coli</i> antimicrobial compounds |
| url | https://www.mdpi.com/2076-0817/9/5/319 |
| work_keys_str_mv | AT magdalenapajor ipaenibacillusalveimp1iasaproduceroftheproteinaceouscompoundwithactivityagainstimportanthumanpathogensincludingistaphylococcusaureusiandilisteriamonocytogenesi AT ziruirayxiong ipaenibacillusalveimp1iasaproduceroftheproteinaceouscompoundwithactivityagainstimportanthumanpathogensincludingistaphylococcusaureusiandilisteriamonocytogenesi AT randywworobo ipaenibacillusalveimp1iasaproduceroftheproteinaceouscompoundwithactivityagainstimportanthumanpathogensincludingistaphylococcusaureusiandilisteriamonocytogenesi AT piotrszweda ipaenibacillusalveimp1iasaproduceroftheproteinaceouscompoundwithactivityagainstimportanthumanpathogensincludingistaphylococcusaureusiandilisteriamonocytogenesi |